DNMT3A and acute myeloid leukemia: Our research found that NRF2 inhibition can reduce the level of Bcl2, Bcl-xl, and Mcl-1, then in our future work, we will also explore whether NRF2 plays a role in venetoclax resistance to help improve the effects of venetoclax in AML patients with DNMT3A R882 mutation.